ots167
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 23, 2013 (NCT01910545)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
FLT3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ots167
- ots167
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02926690 | Phase 1 | May 29, 2017 | OncoTherapy Science, Inc. |
| NCT02795520 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2016 | OncoTherapy Science, Inc., University of Chicago |
| NCT02768519 | Phase 1 | Jan 1, 2016 | IDT Australia Ltd., OncoTherapy Science, Inc. |
| NCT01910545 | Phase 1 | Aug 23, 2013 | OncoTherapy Science, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| OncoTherapy Science, Inc. | For profit | 4 | 4 | 2 | 2013 |
| IDT Australia Ltd. | For profit | 1 | 0 | 1 | 2016 |
| University of Chicago | Academic/Hospital | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1